BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24053191)

  • 21. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
    Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
    J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
    Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
    Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
    Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
    Ferolla P; Berruti A; Spada F; Brizzi MP; Ibrahim T; Marconcini R; Giuffrida D; Amoroso V; La Salvia A; Vaccaro V; Faggiano A; Colao A; Volante M; Ghizzoni S; Mazzanti P; Houchard A; Fazio N
    Neuroendocrinology; 2023; 113(3):332-342. PubMed ID: 36044870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
    Lepage C; Phelip JM; Lievre A; Le-Malicot K; Dahan L; Tougeron D; Toumpanakis C; Di-Fiore F; Lombard-Bohas C; Borbath I; Coriat R; Lecomte T; Guimbaud R; Petorin C; Legoux JL; Michel P; Scoazec JY; Smith D; Walter T
    Eur J Cancer; 2022 Nov; 175():31-40. PubMed ID: 36087395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
    Witek P; Mucha S; Ruchała M
    Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
    Lepage C; Dahan L; Bouarioua N; Toumpanakis C; Legoux JL; Le Malicot K; Guimbaud R; Smith D; Tougeron D; Lievre A; Cadiot G; Di Fiore F; Bouhier-Leporrier K; Hentic O; Faroux R; Pavel M; Borbath I; Valle JW; Rinke A; Scoazec JY; Ducreux M; Walter T
    Dig Liver Dis; 2017 May; 49(5):568-571. PubMed ID: 28292641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
    Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
    Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
    Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.
    Ito T; Fujimori N; Honma Y; Kudo A; Hijioka S; Katsushima S; Kimura Y; Fukutomi A; Hisamatsu S; Nakajima A; Shimatsu A
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e153-e161. PubMed ID: 32757459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.